Abstract
Abstract Capecitabine is a widely used and effective oral chemotherapeutic agent for metastatic breast cancer and colorectal cancer; however, it is associated with several adverse effects. Of these effects, hand–foot syndrome (HFS) or palmar–plantar erythrodysesthesia, characterized by chronic inflammation, particularly of the hands and feet, is most notable. Chronic inflammation increases the risk of squamous cell cancers. We present a unique case of a patient with metastatic breast cancer whose disease was controlled with capecitabine for over a decade. She experienced chronic grade 1–2 HFS and subsequently developed squamous cell skin cancer on the palms and soles. To the best of our knowledge, squamous cell cancer associated with capecitabine exposure has not been previously reported. This case report aims to shed light on this association, thereby expanding the existing literature on the topic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
